Close Menu

hereditary cancer

Invitae has received accreditation for its laboratory from the College of American Pathologists as well as coverage eligibility from Blue Shield of California and the Centers for Medicare and Medicaid Services.

Data presented at AMP compares clinical performance of InVitae's next-generation sequencing-based hereditary cancer risk test compared to BRCA1/2 testing alone.

Genetic testing laboratory Pathway Genomics today announced a partnership with the Prospective Registry of Multiplex Testing, an online registry for patients who have undergone testing for cancer-causing genetic mutations. Pathway Genomics will provide information about the registry to patients and healthcare providers receiving panel tests.

NEW YORK (GenomeWeb) – While industry observers might disagree about whether GeneDx's decision to apply for inter partes review (IPR) of 11 patents held by Myriad Genetics will work in its favor, they generally concur that it is a quicker and less costly strategy than litigation.

NEW YORK (GenomeWeb News) – A new study suggests gene panels can pick up potentially pathogenic variants in hereditary, cancer-related genes in a clinical setting — in some cases leading to more aggressive screening and detection strategies.

Researchers in the department of genetics at The Netherlands' University of Groningen are working to develop targeted next-generation sequencing panels to replace the Sanger sequencing that has previously been the group's standard in several disease areas.

NEW YORK (GenomeWeb News) – Myriad Genetics will adopt RainDance Technologies' microdroplet PCR-based target enrichment technology for use in a next-generation sequencing-based hereditary cancer panel test that Myriad is currently developing, the companies said today.

In preparation for the launch, the laboratory is currently exploring the test in a clinical research setting and is hoping to sequence its first genome next month.

During Myriad's investor day last week, officials disclosed that the firm is working with pharmaceutical companies to develop companion diagnostics for PARP inhibitors and PTEN inhibitors.

Pages

The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.

In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.

MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.

In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.